Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience

[1]  Lars Kjeldsen,et al.  Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Naoe,et al.  The demarcation between younger and older acute myeloid leukemia patients: A pooled analysis of 3 prospective studies , 2013, Cancer.

[3]  Matthew P Wright,et al.  Acute myeloid leukaemia in Western Australia 1991–2005: a retrospective population‐based study of 898 patients regarding epidemiology, cytogenetics, treatment and outcome , 2013, Internal medicine journal.

[4]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[5]  F. Solé,et al.  Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Löwenberg.  Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. , 2013, Blood.

[7]  C. Bloomfield,et al.  Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Weisdorf,et al.  Survival for older patients with acute myeloid leukemia: a population-based study , 2012, Haematologica.

[9]  A. Kohlmann,et al.  A novel hierarchical prognostic model of AML solely based on molecular mutations. , 2012, Blood.

[10]  R. Schlenk,et al.  The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach , 2012, Nature Reviews Clinical Oncology.

[11]  E. Vellenga,et al.  Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Juliusson,et al.  Acute myeloid leukemia in the real world: why population-based registries are needed. , 2012, Blood.

[13]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[14]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Sekeres.  My AML cytogenetics classification scheme is better than yours. , 2012, Biology of Blood and Marrow Transplantation.

[16]  K. Döhner,et al.  Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. , 2012, Blood.

[17]  L. Möllgård,et al.  Hematopoietic stem cell transplantation rates and long‐term survival in acute myeloid and lymphoblastic leukemia , 2011, Cancer.

[18]  K. Wagner,et al.  Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. , 2011, Blood.

[19]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[20]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[21]  H. Döhner,et al.  High-dose daunorubicin in older patients with acute myeloid leukemia. , 2009, The New England journal of medicine.

[22]  Hisashi Sakamaki,et al.  Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. , 2009, JAMA.

[23]  Keith Wheatley,et al.  Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials , 2009, British journal of haematology.

[24]  M. Lin,et al.  Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China , 2009, Leukemia.

[25]  Sören Lehmann,et al.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. , 2009, Blood.

[26]  A. Hagemeijer,et al.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[28]  S. Fröhling,et al.  Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. , 2006, Blood.

[29]  S. Ogston,et al.  Population-based demographic study of karyotypes in 1709 patients with adult Acute Myeloid Leukemia , 2006, Leukemia.

[30]  K. Schmidt,et al.  Cytogenetic findings in adult de novo acute myeloid leukaemia. A population‐based study of 303/337 patients , 2003, British journal of haematology.

[31]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[32]  A. Wåhlin,et al.  Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia , 2001, British journal of haematology.

[33]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[34]  F. Wiklund,et al.  Attitude towards remission induction for elderly patients with acute myeloid leukemia influences survival , 2006, Leukemia.

[35]  W. Hiddemann,et al.  Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia. , 2005, Haematologica.

[36]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .